Boston Scientific’s 2027 Reset: A Buying Opportunity or a Value Trap?

What happened

Boston Scientific has slashed 2026 guidance and acknowledged worse-than-expected competitive pressures in its WATCHMAN and electrophysiology segments, driving a sharp stock decline. The Seeking Alpha article argues the reset has washed out expectations, making the stock attractive at 13.7x forward earnings with 44% upside to a $66 price target if negative earnings revisions stabilize. Our DeepValue report, however, rates BSX a WAIT, citing unresolved risks around EP share stabilization and the financing of the ~$14.5B Penumbra acquisition. The divergence hinges on whether the reset is a one-time clearing event or the first of multiple cuts.

Implication

If management delivers stabilization in EP and WATCHMAN trends by late 2026 and avoids leverage strain from the Penumbra deal, the stock could re-rate to the mid-$60s; conversely, failure to stabilize or covenant stress could drive shares toward the $45 bear case. Investors should monitor Q2 2026 earnings for early signs of a turnaround.

Thesis delta

The thesis shifts from a pure WAIT to a potential accumulation window if guidance is now derisked. The article’s buy rating highlights an attractive valuation, but the DeepValue report underscores that operational stabilization remains unproven. The delta is that the risk/reward has improved at lower prices, but conviction requires confirmation that the worst of the competitive share loss is behind the company.